3 Stocks to Watch For: Valero Energy Corporation (VLO), The Dow Chemical Company (DOW), Mylan N.V. (MYL)

Valero Energy Corporation (VLO) saw its value decrease by -1.71% as the stock dropped $-1.16 to finish the day at a closing price of $66.6. The stock was lighter in trading and has fluctuated between $46.88-$71.4 per share for the past year. The shares, which traded within a range of $66.39 to $67.61 during the day, are up by 7.57% in the past three months and up by 23.13% over the past six months. It is currently trading 0.67% above its 20 day moving average and 0.13% above its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $73.09 a share over the next twelve months. The current relative strength index (RSI) reading is 51.23.The technical indicator lead us to believe there will be no major movement any time soon, hold.

Valero Energy Corporation operates as an independent petroleum refining and marketing company in the United States, Canada, the Caribbean, the United Kingdom, and Ireland. It operates through two segments, Refining and Ethanol. The Refining segment is involved in refining, wholesale marketing, and bulk sales and trading activities. This segment produces conventional and premium gasolines, gasoline meeting the specifications of the California Air Resources Board (CARB), reformulated gasoline blendstock for oxygenate blending, diesel fuels, low-sulfur and ultra-low-sulfur diesel fuels, CARB diesel fuel, distillates, jet fuels, asphalts, petrochemicals, lubricants, and other refined products. As of February 19, 2016, it owned 15 petroleum refineries with a combined throughput capacity of approximately 3.0 million barrels per day. This segment also markets its refined products through bulk and rack marketing network; and through approximately 7,500 outlets under the Valero, Diamond Shamrock, Shamrock, Ultramar, Beacon, and Texaco brand names. The Ethanol segment produces and sells ethanol and distillers grains primarily to refiners and gasoline blenders, as well as to animal feed customers. This segment operates 11 ethanol plants with a combined ethanol production capacity of approximately 1.4 billion gallons per year. The company also operates a 50-megawatt wind farm; convenience stores; filling stations, as well as truckstop, cardlock, and home heating oil facilities; and credit card business. The company was formerly known as Valero Refining and Marketing Company and changed its name to Valero Energy Corporation in August 1997. Valero Energy Corporation was founded in 1955 and is headquartered in San Antonio, Texas.

The Dow Chemical Company (DOW) shares were up in last trading by 0.51% to $61.41. It experienced lighter than average volume on day. The stock increased in value by almost 1.91% over the past week and grew 6.41% in the past month. It is currently trading 4.83% above its 50 day moving average and 14.62% above its 200 day moving average. Following the recent increase in price, the stock’s new closing price represents a -0.71% decrease in value from its one year high of $61.85. The RSI indicator value of 62.41, lead us to believe that it is a hold for now.

The Dow Chemical Company manufactures and supplies products that are used primarily as raw materials in the manufacture of customer products and services worldwide. It operates through five segments: Agricultural Sciences, Consumer Solutions, Infrastructure Solutions, Performance Materials & Chemicals, and Performance Plastics segments. The Agricultural Sciences segment provides crop protection and seed/plant biotechnology products and technologies, urban pest management solutions, and healthy oils. The Consumer Solutions segment offers semiconductors and organic light-emitting diodes, adhesives, and foams for use in the transportation industry; cellulosics and other polymers for pharmaceutical formulations and food solutions; and silicone solutions used in consumer goods and automotive applications. The Infrastructure Solutions segment provides architectural and industrial coatings, construction material ingredients, building insulation products, adhesives, and microbial protection products for the oil and gas industry, telecommunications, and light and water technologies. The Performance Materials & Chemicals segment offers chlorine and caustic soda; industrial solutions; and propylene oxides, propylene glycols, polyether polyols, and aromatic isocyanates. The Performance Plastics segment provides elastomers, polyolefin plastomers, and ethylene propylene diene monomer elastomers; wire and cable insulation, semiconductive, and jacketing compound solutions, as well as bio-based plasticizers; acrylics, polyethylene, and polyolefin plastomers; and ethylene, propylene, benzene, butadiene, octene, aromatics co-products, and crude c4. The company was founded in 1897 and is based in Midland, Michigan.

Mylan N.V. (MYL) traded within a range of $41.56 to $42.65 after opening the day at $42.6. The company has seen its stock increase in value by 10.09% so far this year. The stock was down close to -1.04% on light volume in last trading session and closed at $42 per share. After the recent fall, the stock is currently holding -16.67% below its 52 week high of $50.4 and 25% above its 12-month low of $33.6. The shares are up by over 8.64% in the last three months, and the RSI indicator value of 71.33 is bearish. The technical indicator is offering a warning sign that the stock can’t keep current pace going.

Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals worldwide. The company provides generic or branded generic pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, cream, or ointment forms, as well as active pharmaceutical ingredients (APIs). It is also involved in the development of APIs with non-infringing processes for internal use and to partner with manufacturers; and manufacture and sale of injectable products in antineoplastics, anti-infectives, anesthesia/pain management, and cardiovascular therapeutic areas. In addition, the company produces finished dosage form and oral solid dose products; and offers antiretroviral therapies to third parties. Further, it manufactures and sells branded specialty injectable and nebulized products comprising EpiPen Auto-Injector to treat severe allergic reactions; Perforomist Inhalation Solution, a formoterol fumarate inhalation solution for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder patients; and ULTIVA, an analgesic agent used during the induction and maintenance of general anesthesia for inpatient and outpatient procedures. It sells generic pharmaceutical products to proprietary and ethical pharmaceutical wholesalers and distributors, group purchasing organizations, drug store chains, independent pharmacies, drug manufacturers, institutions, and public and governmental agencies; and specialty pharmaceuticals to pharmaceutical wholesalers and distributors, pharmacies, and healthcare institutions. Mylan N.V. has a collaboration agreement with Momenta Pharmaceuticals, Inc. to develop, manufacture, and commercialize Momenta Pharmaceuticals, Inc.’s biosimilar candidates. The company was formerly known as New Moon B.V. Mylan N.V. was founded in 1961 and is based in Hertfordshire, the United Kingdom.

 

Three Movers to Watch for: MetLife, Inc. (MET), Mylan N.V. (MYL), Alexion Pharmaceuticals, Inc. (ALXN)

MetLife, Inc. (MET) grew with the stock adding 0.71% or $0.38 to close at $53.88 on light trading volume of 4.93M compared its three months average trading volume of 6M. The New York New York 10166 based company operating under the Life Insurance industry has been trending up for the last 52 weeks, with the shares price now 46.67% up for the period and up by 0.72% so far this year. With price target of $59.86 and a 52.77% rebound from 52-week low, MetLife, Inc. has plenty of upside potential, making it a hold with a view buy.

MetLife, Inc. provides life insurance, annuities, employee benefits, and asset management products in the United States, Japan, Latin America, Asia, Europe, and the Middle East. It operates in six segments: Retail; Group, Voluntary & Worksite Benefits; Corporate Benefit Funding; Latin America; Asia; and Europe, the Middle East and Africa. The company provides variable, universal, term, and whole life products; individual disability income products; personal lines property and casualty insurance, including private passenger automobile, homeowners, and personal excess liability insurance; and variable and fixed annuities for asset accumulation and distribution needs, as well as mutual funds and other securities products. It also offers group insurance products, such as variable, universal, and term life products; dental, group short- and long-term disability, and accidental death and dismemberment coverages; and voluntary and worksite products consisting of personal lines property and casualty insurance, as well as LTC, prepaid legal plans, and critical illness products. In addition, the company provides annuity and investment products comprising guaranteed interest products and other stable value products, income annuities, and separate account contracts for the investment management of defined benefit and defined contribution plan assets; and structured settlements and products to fund postretirement benefits and company-, bank- or trust-owned life insurance, as well as health insurance, group medical, credit insurance, endowment, retirement, and savings products. It serves individuals and corporations, as well as other institutions and their employees. The company sells its products through sales forces, third-party organizations, independent agents, and property and casualty specialists, as well as through career agency, bancassurance, direct marketing, brokerage, and e-commerce channels. MetLife, Inc. was founded in 1863 and is based in New York, New York.

Mylan N.V. (MYL) gained $0.97 to close the day at a new closing price of $40.75, a 2.44% increase in value from its previous closing price that moved the stock 21.28% above its 52 week low of $33.6. A total of 5.5M shares exchanged hands during the day compared with its three month average trading volume of 5.03M. The stock, which fluctuated between $39.56 and $40.91 during the day, currently situated -19.15% below its 52 week high. The stock is up by 10.94% in the past one month and up by 7.43% over the past three months. With a one year target estimate of $49.84 and RSI of 69.18, the stock still has upside potential, making it a hold for now.

Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals worldwide. The company provides generic or branded generic pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, cream, or ointment forms, as well as active pharmaceutical ingredients (APIs). It is also involved in the development of APIs with non-infringing processes for internal use and to partner with manufacturers; and manufacture and sale of injectable products in antineoplastics, anti-infectives, anesthesia/pain management, and cardiovascular therapeutic areas. In addition, the company produces finished dosage form and oral solid dose products; and offers antiretroviral therapies to third parties. Further, it manufactures and sells branded specialty injectable and nebulized products comprising EpiPen Auto-Injector to treat severe allergic reactions; Perforomist Inhalation Solution, a formoterol fumarate inhalation solution for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder patients; and ULTIVA, an analgesic agent used during the induction and maintenance of general anesthesia for inpatient and outpatient procedures. It sells generic pharmaceutical products to proprietary and ethical pharmaceutical wholesalers and distributors, group purchasing organizations, drug store chains, independent pharmacies, drug manufacturers, institutions, and public and governmental agencies; and specialty pharmaceuticals to pharmaceutical wholesalers and distributors, pharmacies, and healthcare institutions. Mylan N.V. has a collaboration agreement with Momenta Pharmaceuticals, Inc. to develop, manufacture, and commercialize Momenta Pharmaceuticals, Inc.’s biosimilar candidates. The company was formerly known as New Moon B.V. Mylan N.V. was founded in 1961 and is based in Hertfordshire, the United Kingdom.

Alexion Pharmaceuticals, Inc. (ALXN) shares were up in last trading by 1.35% to $129.5. It experienced higher than average volume on day. The stock increased in value by almost 1.39% over the past week and fell -5.43% in the past month. It is currently trading 1.49% above its 50 day moving average and 0.36% above its 200 day moving average. Following the recent increase in price, the stock’s new closing price represents a -20.06% decrease in value from its one year high of $162. The RSI indicator value of 53.53, lead us to believe that it is a hold for now.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. It provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia (HPP); and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. The company also conducts Phase IV clinical trials on Soliris for the treatment of PNH registry; Phase III clinical trials for the treatment of myasthenia gravis, neuromyelitis optica spectrum disorder, and delayed kidney transplant graft function; and Phase II clinical trials for antibody mediated rejection in presensitized renal transplant patients. It develops cPMP (ALXN 1101) that is in Phase II/III trial for treating metabolic disorders; and ALXN 1007, a novel humanized antibody in Phase II clinical trial for the treatment of anti-phospholipid syndrome and graft versus host disease. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other health care providers, as well as governments and government agencies in the United States, Europe, the Asia Pacific, and internationally. Alexion Pharmaceuticals, Inc. has agreements with X-Chem Pharmaceuticals (X-Chem) to identify novel drug candidates from X-Chem’s proprietary drug discovery engine; Moderna Therapeutics, Inc. (Moderna) that provides the option to purchase drug products for clinical development commercialization of Moderna’s messenger RNA therapeutics to treat rare diseases; and Ensemble Therapeutics Corporation for the identification, development, and commercialization of therapeutic candidates based on specific drug targets. The company was founded in 1992 and is headquartered in New Haven, Connecticut.

 

Trader Alert: Mylan N.V. (MYL), Akamai Technologies, Inc. (AKAM), Continental Resources, Inc. (CLR)

Mylan N.V. (MYL) grew with the stock adding 0.03% or $0.01 to close at $39.31 on light trading volume of 2.52M compared its three months average trading volume of 5.2M. The Hatfield Hertfordshire EN6 1AG based company operating under the Drugs – Generic industry has been trending down for the last 52 weeks, with the shares price now -5.09% down for the period and up by 3.04% so far this year. With price target of $49.84 and a 16.99% rebound from 52-week low, Mylan N.V. has plenty of upside potential, making it a hold with a view buy.

Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals worldwide. The company provides generic or branded generic pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, cream, or ointment forms, as well as active pharmaceutical ingredients (APIs). It is also involved in the development of APIs with non-infringing processes for internal use and to partner with manufacturers; and manufacture and sale of injectable products in antineoplastics, anti-infectives, anesthesia/pain management, and cardiovascular therapeutic areas. In addition, the company produces finished dosage form and oral solid dose products; and offers antiretroviral therapies to third parties. Further, it manufactures and sells branded specialty injectable and nebulized products comprising EpiPen Auto-Injector to treat severe allergic reactions; Perforomist Inhalation Solution, a formoterol fumarate inhalation solution for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder patients; and ULTIVA, an analgesic agent used during the induction and maintenance of general anesthesia for inpatient and outpatient procedures. It sells generic pharmaceutical products to proprietary and ethical pharmaceutical wholesalers and distributors, group purchasing organizations, drug store chains, independent pharmacies, drug manufacturers, institutions, and public and governmental agencies; and specialty pharmaceuticals to pharmaceutical wholesalers and distributors, pharmacies, and healthcare institutions. Mylan N.V. has a collaboration agreement with Momenta Pharmaceuticals, Inc. to develop, manufacture, and commercialize Momenta Pharmaceuticals, Inc.’s biosimilar candidates. The company was formerly known as New Moon B.V. Mylan N.V. was founded in 1961 and is based in Hertfordshire, the United Kingdom.

Akamai Technologies, Inc. (AKAM) gained $0.1 to close the day at a new closing price of $63.95, a 0.16% increase in value from its previous closing price that moved the stock 43.13% above its 52 week low of $47.8. A total of 2.51M shares exchanged hands during the day compared with its three month average trading volume of 1.88M. The stock, which fluctuated between $63.5 and $64.28 during the day, currently situated -10.73% below its 52 week high. The stock is down by -8.8% in the past one month and down by -3.88% over the past three months. With a one year target estimate of $71.85 and RSI of 35.34, the stock still has upside potential, making it a hold for now.

Akamai Technologies, Inc. provides cloud services for delivering, optimizing, and securing content and business applications over the Internet in the United States and internationally. The company offers performance and security solutions designed to help Websites and business applications operate while offering protection against security threats. It also provides media content delivery solutions that are designed to deliver movies, television shows, live events, games, social media, software downloads, and other content on the Internet in fixed line and mobile networks; adaptive delivery solutions for streaming video content; and download delivery solution that offers accelerated distribution for large file downloads, including games, progressive media files, documents, and other file-based content. In addition, the company offers a suite of analytics tools to monitor online video viewer experiences and the effectiveness of Web software downloads, while measuring audience engagement, and quality of service performance; and NetStorage, a cloud storage solution, as well as media services to deliver live and on-demand content to various devices and platforms. Further, it provides cloud security solutions, which help customers avoid data theft and downtime, and protect Internet-facing infrastructure; and cloud networking solutions to help customers enhance enterprise branch office and retail store productivity and revenue by accelerating applications, reducing bandwidth costs, and extending the Internet and public clouds into private wide area networks. Additionally, the company offers network operator solutions that are designed to help carriers to operate a network that capitalizes on traffic growth and new subscriber services; and professional services and solutions. It sells its solutions through direct sales and service organization; and through active channel partners. The company was founded in 1998 and is headquartered in Cambridge, Massachusetts.

Continental Resources, Inc. (CLR) shares were up in last trading by 1.62% to $46.52. It experienced lighter than average volume on day. The stock decreased in value by almost -3% over the past week and fell -9.09% in the past month. It is currently trading -9.93% below its 50 day moving average and -1.9% below its 200 day moving average. Following the recent increase in price, the stock’s new closing price represents a -22.85% decrease in value from its one year high of $60.3. The RSI indicator value of 36.63, lead us to believe that it is a hold for now.

Continental Resources, Inc. explores for, develops, and produces crude oil and natural gas properties in the north, south, and east regions of the United States. The company sells its crude oil and natural gas production to energy marketing companies, crude oil refining companies, and natural gas gathering and processing companies. As of December 31, 2015, its estimated proved reserves were 1,226 million barrels of crude oil equivalent (MMBoe) with estimated proved developed reserves of 525 MMBoe. Continental Resources, Inc. was founded in 1967 and is based in Oklahoma City, Oklahoma.

 

Stocks Under Review: Mylan N.V. (MYL), Merck & Co., Inc. (MRK), Texas Instruments Incorporated (TXN)

Mylan N.V. (MYL) continued its downward trend with the stock declining -0.51% or $-0.2 to close the day at $39.19 on active trading volume of 5.93M shares, compared to its three month average trading volume of 5.44M. The Hatfield Hertfordshire EN6 1AG based company has been underperforming the drugs – generic group over the past 52 weeks, with the stock losing -22.76%, compared to the industry which has dropped -3.74% over the same period. With RSI of 60.91, the stock should still continue to rise and get closer to its one year target estimate of $49.84, making it a hold for now.

Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals worldwide. The company provides generic or branded generic pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, cream, or ointment forms, as well as active pharmaceutical ingredients (APIs). It is also involved in the development of APIs with non-infringing processes for internal use and to partner with manufacturers; and manufacture and sale of injectable products in antineoplastics, anti-infectives, anesthesia/pain management, and cardiovascular therapeutic areas. In addition, the company produces finished dosage form and oral solid dose products; and offers antiretroviral therapies to third parties. Further, it manufactures and sells branded specialty injectable and nebulized products comprising EpiPen Auto-Injector to treat severe allergic reactions; Perforomist Inhalation Solution, a formoterol fumarate inhalation solution for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder patients; and ULTIVA, an analgesic agent used during the induction and maintenance of general anesthesia for inpatient and outpatient procedures. It sells generic pharmaceutical products to proprietary and ethical pharmaceutical wholesalers and distributors, group purchasing organizations, drug store chains, independent pharmacies, drug manufacturers, institutions, and public and governmental agencies; and specialty pharmaceuticals to pharmaceutical wholesalers and distributors, pharmacies, and healthcare institutions. Mylan N.V. has a collaboration agreement with Momenta Pharmaceuticals, Inc. to develop, manufacture, and commercialize Momenta Pharmaceuticals, Inc.’s biosimilar candidates. The company was formerly known as New Moon B.V. Mylan N.V. was founded in 1961 and is based in Hertfordshire, the United Kingdom.

Merck & Co., Inc. (MRK) grew with the stock adding 0.19% or $0.12 to close at $64.32 on active trading volume of 5.9M compared its three months average trading volume of 11.22M. The Kenilworth New Jersey 07033 based company operating under the Drug Manufacturers – Major industry has been trending up for the last 52 weeks, with the shares price now 35.06% up for the period and up by 9.26% so far this year. With price target of $0 and a 38.41% rebound from 52-week low, Merck & Co., Inc. has plenty of upside potential, making it a hold with a view buy.

Merck & Co., Inc. provides healthcare solutions worldwide. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal infections, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, male pattern hair loss, and fertility diseases. It also offers neuromuscular blocking agents; anti-bacterial products; cholesterol modifying medicines; non-sedating antihistamine; and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat brain tumors; treat melanoma and metastatic non-small-cell lung cancer; prevent diseases caused by human papillomavirus; and vaccines for measles, mumps, rubella, varicella, chickenpox, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it offers antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics and vaccines for fishes. Additionally, the company offers companion animal products, such as ointments for otitis; diabetes mellitus treatment for dogs and cats; anthelmintic products; chewable tablets to treat fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. It serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, physician distributors, veterinarians, distributors, animal producers, and managed health care providers. The company has collaboration agreements with Adaptimmune Therapeutics plc and Agenus; and a research agreement with Proteros Biostructures to develop molecule compounds for various cancer treatments. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Texas Instruments Incorporated (TXN) continued its downward trend with the stock declining -0.3% or $-0.23 to close the day at $75.95 on higher than average trading volume of 5.86M shares, compared to its three month average trading volume of 5.43M. The Dallas Texas 75243 based company has been outperforming the semiconductor – broad line companies by 10.6366% for last three months and its recent gains have pushed the stock slightly up 4.74% YTD, versus the semiconductor – broad line industry which is up 7.1% for the same period. The RSI of 54.33 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

Texas Instruments Incorporated designs, manufactures, and sells semiconductors to electronics designers and manufacturers worldwide. It operates through two segments, Analog and Embedded Processing. The Analog segment offers high volume analog and logic products for automotive safety devices, touch screen controllers, low voltage motor drivers, and integrated motor controllers; and power management products that include catalog and application-specific standard products to enhance the efficiency of powered devices using battery management solutions, portable power conversion devices, power supply controls, and point-of-load products. This segment also provides high performance analog products, such as high-speed data converters, amplifiers, sensors, high reliability products, interface products, and precision products; and silicon valley analog products, including power management, data converter, interface, and operational amplifier catalog analog products that are used in manufacturing various electronic systems. The Embedded Processing segment offers microcontroller products, which are systems with a processor core, memory, and peripherals to control a set of specific tasks for electronic equipment; processor products comprising digital signal and applications processors; and connectivity products consisting of electronic devices to connect and transfer data. The company also provides DLP products primarily used in projectors to create high-definition images; application-specific integrated circuits; calculators; and baseband products, as well as OMAP applications processors and connectivity products. It markets and sells its products through a direct sales force and distributors. Texas Instruments Incorporated was founded in 1930 and is headquartered in Dallas, Texas.

 

Stocks Under Consideration: Mylan N.V. (MYL), Host Hotels & Resorts, Inc. (HST), Target Corporation (TGT)

Mylan N.V. (MYL) grew with the stock adding 1.96% or $0.77 to close at $39.98 on active trading volume of 6.05M compared its three months average trading volume of 5.46M. The Hatfield Hertfordshire EN6 1AG based company operating under the Drugs – Generic industry has been trending down for the last 52 weeks, with the shares price now -22.2% down for the period and up by 4.8% so far this year. With price target of $49.84 and a 18.99% rebound from 52-week low, Mylan N.V. has plenty of upside potential, making it a hold with a view buy.

Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals worldwide. The company provides generic or branded generic pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, cream, or ointment forms, as well as active pharmaceutical ingredients (APIs). It is also involved in the development of APIs with non-infringing processes for internal use and to partner with manufacturers; and manufacture and sale of injectable products in antineoplastics, anti-infectives, anesthesia/pain management, and cardiovascular therapeutic areas. In addition, the company produces finished dosage form and oral solid dose products; and offers antiretroviral therapies to third parties. Further, it manufactures and sells branded specialty injectable and nebulized products comprising EpiPen Auto-Injector to treat severe allergic reactions; Perforomist Inhalation Solution, a formoterol fumarate inhalation solution for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder patients; and ULTIVA, an analgesic agent used during the induction and maintenance of general anesthesia for inpatient and outpatient procedures. It sells generic pharmaceutical products to proprietary and ethical pharmaceutical wholesalers and distributors, group purchasing organizations, drug store chains, independent pharmacies, drug manufacturers, institutions, and public and governmental agencies; and specialty pharmaceuticals to pharmaceutical wholesalers and distributors, pharmacies, and healthcare institutions. Mylan N.V. has a collaboration agreement with Momenta Pharmaceuticals, Inc. to develop, manufacture, and commercialize Momenta Pharmaceuticals, Inc.’s biosimilar candidates. The company was formerly known as New Moon B.V. Mylan N.V. was founded in 1961 and is based in Hertfordshire, the United Kingdom.

Host Hotels & Resorts, Inc. (HST) had a active trading with around 6.02M shares changing hands compared to its three month average trading volume of 10.74M. The stock traded between $17.81 and $18.19 before closing at the price of $17.88 with -1.16% change on the day. The Bethesda Maryland 20817 based company is currently trading 40.45% above its 52 week low of $13.56 and -8.21% below its 52 week high of $19.51. Both the RSI indicator and target price of  and $18.18 respectively, lead us to believe that it could rise over the coming weeks.

Host Hotels & Resorts, Inc. is a publicly owned real estate investment trust (REIT). The firm primarily engages in the ownership and operation of hotel properties. It invests in the real estate markets of United States. It also invests in Canada, Mexico, Chile, the United Kingdom, Italy, Spain, and Poland. The firm primarily invests in luxury and upper upscale hotels. It was formerly known as Host Marriott Corporation. Host Hotels & Resorts, Inc. was founded in 1927 and is based in Bethesda, Maryland.

Target Corporation (TGT) saw its value decrease by -0.52% as the stock dropped $-0.33 to finish the day at a closing price of $63.42. The stock was lighter in trading and has fluctuated between $62.94-$84.14 per share for the past year. The shares, which traded within a range of $63.36 to $63.95 during the day, are down by -4.07% in the past three months and down by -13.97% over the past six months. It is currently trading -5.02% below its 20 day moving average and -12.41% below its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $73.85 a share over the next twelve months. The current relative strength index (RSI) reading is 25.52.The technical indicator lead us to believe the stock will reverse recent losses any time soon.

Target Corporation operates as a general merchandise retailer. It offers household essentials, including pharmacy, beauty, personal care, baby care, cleaning, and paper products; music, movies, books, computer software, sporting goods, and toys, as well as electronics, such as video game hardware and software; and apparel for women, men, boys, girls, toddlers, infants, and newborns, as well as intimate apparel, jewelry, accessories, and shoes. The company also provides food and pet supplies comprising dry grocery, dairy, frozen food, beverages, candy, snacks, deli, bakery, meat, produce, and pet supplies; and home furnishings and décor, including furniture, lighting, kitchenware, small appliances, home décor, bed and bath, home improvement, and automotive products, as well as seasonal merchandise, such as patio furniture and holiday décor. In addition, it offers in-store amenities, including Target Café, Target Photo, Target Optical, Portrait Studio, Starbucks, and other food service offerings. Target Corporation sells products through its stores; and digital channels, including Target.com. As of January 30, 2016, the company operated 1,792 stores in the United States. Target Corporation was founded in 1902 and is headquartered in Minneapolis, Minnesota.

 

Stocks Under Review: CenturyLink, Inc. (CTL), Halliburton Company (HAL), Mylan N.V. (MYL)

CenturyLink, Inc. (CTL) continued its downward trend with the stock declining -0.98% or $-0.25 to close the day at $25.26 on light trading volume of 6.19M shares, compared to its three month average trading volume of 9.08M. The Monroe Louisiana 71203 based company has been outperforming the telecom services – domestic group over the past 52 weeks, with the stock gaining 4.74%, compared to the industry which has advanced 8.65% over the same period. With RSI of 50.06, the stock should still continue to rise and get closer to its one year target estimate of $28.58, making it a hold for now.

CenturyLink, Inc. provides various communications services to residential, business, wholesale, and governmental customers in the United States. It operates through two segments, Business and Consumer. The company offers high-speed Internet services, which allow customers to connect to the Internet through their existing telephone lines or fiber-optic cables; multi-protocol label switching, a data networking technology to support real-time voice and video; and private line services for the transmission of data between sites. It also provides Ethernet services, including point-to-point and multi-point equipment configurations that facilitate data transmissions across metropolitan areas and wide area networks (WAN); colocation services that enable its customers to install their own information technology (IT) equipment; and managed hosting services comprising cloud and traditional computing, application management, back-up, storage, and other services. In addition, the company offers video entertainment services and satellite digital television; Voice over Internet Protocol, a real-time, two-way voice communication service; and managed services that consist of network, hosting, cloud, and IT services. Further, it provides local calling, long-distance voice, integrated services digital network, WAN, and switched access services; and data integration, which includes the sale of telecommunications equipment and providing network management, installation, and maintenance of data equipment, and the building of proprietary fiber-optic broadband networks. Additionally, the company leases and subleases space in its office buildings, warehouses, and other properties. As of December 31, 2015, it served approximately 6 million high-speed Internet subscribers and 285 thousand television subscribers; and operated 59 data centers in North America, Europe, and Asia. CenturyLink, Inc. was founded in 1968 and is headquartered in Monroe, Louisiana.

Halliburton Company (HAL) grew with the stock adding 0.11% or $0.06 to close at $56.29 on light trading volume of 6.18M compared its three months average trading volume of 8.4M. The Houston Texas 77032 based company operating under the Oil & Gas Equipment & Services industry has been trending up for the last 52 weeks, with the shares price now 79.19% up for the period and up by 4.07% so far this year. With price target of $63.11 and a 104.82% rebound from 52-week low, Halliburton Company has plenty of upside potential, making it a hold with a view buy.

Halliburton Company provides a range of services and products to the upstream oil and natural gas industry worldwide. The company’s Completion and Production segment offers production enhancement services, including stimulation and sand control services; and cementing services, such as bonding the well, well casing, and casing equipment. It also provides completion tools that offer downhole solutions and services, including well completion products and services, intelligent well completions, liner hanger systems, sand control systems, and service tools; pressure control services comprising coiled tubing, hydraulic workover units, and downhole tools; and pipeline and process services, such as pre-commissioning and maintenance, subsea pipeline, conventional pipeline, and process services. In addition, this segment offers oilfield production and completion chemicals and services; electrical submersible pumps and progressive cavity pumps; and installation, maintenance, repair, and testing services. The company’s Drilling and Evaluation segment provides drilling fluid systems, performance additives, completion fluids, solids control, specialized testing equipment, and waste management services; and drilling systems and services. It also offers wireline and perforating services that include open-hole logging, cased-hole and slickline, borehole seismic, and formation and reservoir solutions; and drill bits and services comprising roller cone rock bits, fixed cutter bits, hole enlargement, and related downhole tools and services, as well as coring equipment and services. In addition, this segment offers integrated exploration, drilling, and production software, as well as related professional and data management services; testing and subsea services, such as acquisition and analysis of reservoir information and optimization solutions; and oilfield project management and integrated solutions. Halliburton Company was founded in 1919 and is based in Houston, Texas.

Mylan N.V. (MYL) continued its upward trend with the stock climbing 0.88% or $0.34 to close the day at $39 on higher than average trading volume of 6.18M shares, compared to its three month average trading volume of 5.65M. The Hatfield Hertfordshire EN6 1AG based company has been outperforming the drugs – generic companies by 4.8608% for last three months and its recent gains have pushed the stock slightly up 2.23% YTD, versus the drugs – generic industry which is up 6.28% for the same period. The RSI of 62.48 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals worldwide. The company provides generic or branded generic pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, cream, or ointment forms, as well as active pharmaceutical ingredients (APIs). It is also involved in the development of APIs with non-infringing processes for internal use and to partner with manufacturers; and manufacture and sale of injectable products in antineoplastics, anti-infectives, anesthesia/pain management, and cardiovascular therapeutic areas. In addition, the company produces finished dosage form and oral solid dose products; and offers antiretroviral therapies to third parties. Further, it manufactures and sells branded specialty injectable and nebulized products comprising EpiPen Auto-Injector to treat severe allergic reactions; Perforomist Inhalation Solution, a formoterol fumarate inhalation solution for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder patients; and ULTIVA, an analgesic agent used during the induction and maintenance of general anesthesia for inpatient and outpatient procedures. It sells generic pharmaceutical products to proprietary and ethical pharmaceutical wholesalers and distributors, group purchasing organizations, drug store chains, independent pharmacies, drug manufacturers, institutions, and public and governmental agencies; and specialty pharmaceuticals to pharmaceutical wholesalers and distributors, pharmacies, and healthcare institutions. Mylan N.V. has a collaboration agreement with Momenta Pharmaceuticals, Inc. to develop, manufacture, and commercialize Momenta Pharmaceuticals, Inc.’s biosimilar candidates. The company was formerly known as New Moon B.V. Mylan N.V. was founded in 1961 and is based in Hertfordshire, the United Kingdom.

 

Stocks in Review: Mylan N.V. (MYL), Digital Realty Trust, Inc. (DLR), Alexion Pharmaceuticals, Inc. (ALXN)

Mylan N.V. (MYL) traded within a range of $36.41 to $38.09 after opening the day at $37.02. The company has seen its stock decrease in value by -0.26% so far this year. The stock was up close to 4.71% on active volume in last trading session and closed at $38.05 per share. After the recent gain, the stock is currently holding -28.49% below its 52 week high of $53.21 and 13.24% above its 12-month low of $33.6. The shares are up by over 2.31% in the last three months, and the RSI indicator value of 56.71 is neither bullish nor bearish, tempting investors to stay on the sidelines.

Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals worldwide. The company provides generic or branded generic pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, cream, or ointment forms, as well as active pharmaceutical ingredients (APIs). It is also involved in the development of APIs with non-infringing processes for internal use and to partner with manufacturers; and manufacture and sale of injectable products in antineoplastics, anti-infectives, anesthesia/pain management, and cardiovascular therapeutic areas. In addition, the company produces finished dosage form and oral solid dose products; and offers antiretroviral therapies to third parties. Further, it manufactures and sells branded specialty injectable and nebulized products comprising EpiPen Auto-Injector to treat severe allergic reactions; Perforomist Inhalation Solution, a formoterol fumarate inhalation solution for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder patients; and ULTIVA, an analgesic agent used during the induction and maintenance of general anesthesia for inpatient and outpatient procedures. It sells generic pharmaceutical products to proprietary and ethical pharmaceutical wholesalers and distributors, group purchasing organizations, drug store chains, independent pharmacies, drug manufacturers, institutions, and public and governmental agencies; and specialty pharmaceuticals to pharmaceutical wholesalers and distributors, pharmacies, and healthcare institutions. Mylan N.V. has a collaboration agreement with Momenta Pharmaceuticals, Inc. to develop, manufacture, and commercialize Momenta Pharmaceuticals, Inc.’s biosimilar candidates. The company was formerly known as New Moon B.V. Mylan N.V. was founded in 1961 and is based in Hertfordshire, the United Kingdom.

Digital Realty Trust, Inc. (DLR) managed to rebound with the stock climbing 1.14% or $1.21 to close the day at $107.63 on light trading volume of 1.3M shares, compared to its three month average trading volume of 1.5M. The San Francisco California 94111 based company has been outperforming the reit – office group over the past 52 weeks, with the stock gaining 40.33%, compared to the industry which has advanced 31.28% over the same period. With RSI of 72.56, the stock should still continue to rise and get closer to its one year target estimate of $107.73, making it a hold for now.

Digital Realty Trust, Inc., a real estate investment trust (REIT), through its controlling interest in Digital Realty Trust, L.P., engages in the ownership, acquisition, development, redevelopment, and management of technology-related real estate. It focuses on strategically located properties containing applications and operations critical to the day-to-day operations of technology industry tenants and corporate enterprise datacenter users, including the information technology departments of Fortune 1000 companies, and financial services companies. The company’s property portfolio consists of Internet gateway properties, corporate datacenter properties, technology manufacturing properties, and regional or national offices of technology companies. As of December 31, 2008, Digital Realty’s portfolio consisted of 75 properties, including 62 located in North America and 13 located in Europe. Digital Realty Trust has elected to be treated as a REIT for federal income tax purposes and would not be subject to income tax, if it distributes at least 90% of its REIT taxable income to its stockholders. The company was founded in 2004 and is headquartered in San Francisco, California with additional offices in Boston, Chicago, Dallas, Los Angeles, New York, Northern Virginia, and Phoenix, as well as in Dublin, London, and Paris.

Alexion Pharmaceuticals, Inc. (ALXN) gained $2.63 to close the day at a new closing price of $130.68, a 2.05% increase in value from its previous closing price that moved the stock 19.76% above its 52 week low of $109.12. A total of 2.05M shares exchanged hands during the day compared with its three month average trading volume of 3.16M. The stock, which fluctuated between $126.1 and $131.07 during the day, currently situated -19.33% below its 52 week high. The stock is up by 5.7% in the past one month and down by -3.62% over the past three months. With a one year target estimate of $167.93 and RSI of 50.41, the stock still has upside potential, making it a hold for now.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. It provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia (HPP); and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. The company also conducts Phase IV clinical trials on Soliris for the treatment of PNH registry; Phase III clinical trials for the treatment of myasthenia gravis, neuromyelitis optica spectrum disorder, and delayed kidney transplant graft function; and Phase II clinical trials for antibody mediated rejection in presensitized renal transplant patients. It develops cPMP (ALXN 1101) that is in Phase II/III trial for treating metabolic disorders; and ALXN 1007, a novel humanized antibody in Phase II clinical trial for the treatment of anti-phospholipid syndrome and graft versus host disease. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other health care providers, as well as governments and government agencies in the United States, Europe, the Asia Pacific, and internationally. Alexion Pharmaceuticals, Inc. has agreements with X-Chem Pharmaceuticals (X-Chem) to identify novel drug candidates from X-Chem’s proprietary drug discovery engine; Moderna Therapeutics, Inc. (Moderna) that provides the option to purchase drug products for clinical development commercialization of Moderna’s messenger RNA therapeutics to treat rare diseases; and Ensemble Therapeutics Corporation for the identification, development, and commercialization of therapeutic candidates based on specific drug targets. The company was founded in 1992 and is headquartered in New Haven, Connecticut.

 

Stocks in the Spotlight: Alphabet Inc. (GOOG), Mylan N.V. (MYL), TechnipFMC plc (FTI)

Alphabet Inc. (GOOG) had a active trading with around 2.95M shares changing hands compared to its three month average trading volume of 1.74M. The stock traded between $820.44 and $841.95 before closing at the price of $823.31 with -1.06% change on the day. The Mountain View California 94043 based company is currently trading 24.17% above its 52 week low of $663.06 and -1.75% below its 52 week high of $841.95. Both the RSI indicator and target price of 63.36 and $946.22 respectively, lead us to believe that it should be put on hold over the coming weeks.

Alphabet Inc., through its subsidiaries, provides online advertising services in the United States, the United Kingdom, and rest of the world. The company offers performance and brand advertising services. It operates through Google and Other Bets segments. The Google segment includes principal Internet products, such as Search, Ads, Commerce, Maps, YouTube, Apps, Cloud, Android, Chrome, and Google Play, as well as technical infrastructure and newer efforts, such as Virtual Reality. This segment also sells hardware products comprising Chromecast, Chromebooks, and Nexus. The Other Bets segment includes businesses, such as Access/Google Fiber, Calico, Nest, Verily, GV, Google Capital, X, and other initiatives. Alphabet Inc. was founded in 1998 and is headquartered in Mountain View, California.

Mylan N.V. (MYL) managed to rebound with the stock climbing 1.55% or $0.56 to close the day at $36.66 on light trading volume of 2.95M shares, compared to its three month average trading volume of 5.7M. The Hatfield Hertfordshire EN6 1AG based company has been underperforming the drugs – generic group over the past 52 weeks, with the stock losing -27.31%, compared to the industry which has dropped -14.98% over the same period. With RSI of 46.34, the stock should still continue to rise and get closer to its one year target estimate of $49.84, making it a hold for now.

Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals worldwide. The company provides generic or branded generic pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, cream, or ointment forms, as well as active pharmaceutical ingredients (APIs). It is also involved in the development of APIs with non-infringing processes for internal use and to partner with manufacturers; and manufacture and sale of injectable products in antineoplastics, anti-infectives, anesthesia/pain management, and cardiovascular therapeutic areas. In addition, the company produces finished dosage form and oral solid dose products; and offers antiretroviral therapies to third parties. Further, it manufactures and sells branded specialty injectable and nebulized products comprising EpiPen Auto-Injector to treat severe allergic reactions; Perforomist Inhalation Solution, a formoterol fumarate inhalation solution for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder patients; and ULTIVA, an analgesic agent used during the induction and maintenance of general anesthesia for inpatient and outpatient procedures. It sells generic pharmaceutical products to proprietary and ethical pharmaceutical wholesalers and distributors, group purchasing organizations, drug store chains, independent pharmacies, drug manufacturers, institutions, and public and governmental agencies; and specialty pharmaceuticals to pharmaceutical wholesalers and distributors, pharmacies, and healthcare institutions. Mylan N.V. has a collaboration agreement with Momenta Pharmaceuticals, Inc. to develop, manufacture, and commercialize Momenta Pharmaceuticals, Inc.’s biosimilar candidates. The company was formerly known as New Moon B.V. Mylan N.V. was founded in 1961 and is based in Hertfordshire, the United Kingdom.

TechnipFMC plc (FTI) shares were up in last trading by 0.14% to $35.3. It experienced lighter than average volume on day. The stock increased in value by almost 3.4% over the past week and fell -1.04% in the past month. It is currently trading 0.33% above its 50 day moving average and 17.24% above its 200 day moving average. Following the recent increase in price, the stock’s new closing price represents a -4.83% decrease in value from its one year high of $37.09. The RSI indicator value of 52.86, lead us to believe that it is a hold for now.

TechnipFMC plc provides technologies, systems, and services for oil and gas projects worldwide. It operates in three segments: Subsea, Onshore/Offshore, and Surface Projects. The Subsea segment offers products, such as trees, manifolds, controls, templates, flowline systems, umbilicals, and flexibles, as well as subsea processing products. This segment also provides subsea services, including drilling, installation, completion, and field services, as well as asset management, well intervention and IMR, ROVs, and manipulator system services; and services for subsea projects comprising front end to decommissioning, field architecture, integrated design, engineering, procurement, construction, and installation services. The Onshore/Offshore segment offers technical, technological, and project management services across fixed, floating, and onshore facilities, as well as offshore services. The Surface Projects segment provides drilling, completion, and production wellhead equipment, as well as chokes, compact valves, manifolds, and controls; treating iron, manifolds, and reciprocating pumps for stimulation and cementing; separation and flow-treatment systems; flow metering products and systems; marine, truck, and railcar loading systems; installation maintenance services; frac-stack, manifold rental, and operation services; and flowback and well testing services. The company is headquartered in London, the United Kingdom.

 

3 Notable Runners: Union Pacific Corporation (UNP), American Airlines Group Inc. (AAL), Mylan N.V. (MYL)

Union Pacific Corporation (UNP) continued its upward trend with the stock climbing 1.56% or $1.7 to close the day at $110.42 on higher than average trading volume of 5.14M shares, compared to its three month average trading volume of 4.1M. The Omaha Nebraska 68179 based company has been outperforming the railroads companies by 23.4969% for last three months and its recent gains have pushed the stock slightly up 6.5% YTD, versus the railroads industry which is up 23.8% for the same period. The RSI of 70.3 indicates the stock is overbought at the current levels, sell for now.

Union Pacific Corporation, through its subsidiary, Union Pacific Railroad Company, operates railroads in the United States. It offers freight transportation services for agricultural products, including grains, commodities produced from grains, and food and beverage products; automotive products, such as finished vehicles and automotive parts; and chemicals comprising industrial chemicals, plastics, fertilizers, petroleum and liquid petroleum gases, crude oil, and soda ash. The company also provides transportation services for coal and petroleum coke; industrial products consisting of construction products, minerals, consumer goods, metals, lumber, paper, and other miscellaneous products; and intermodal import and export containers and trailers. Union Pacific Corporation’s rail network includes 32,084 route miles linking the Pacific Coast and Gulf Coast ports with the Midwest and eastern United States gateways. The company was founded in 1862 and is headquartered in Omaha, Nebraska.

American Airlines Group Inc. (AAL) had a light trading with around 5.14M shares changing hands compared to its three month average trading volume of 6.3M. The stock traded between $47.61 and $48.21 before closing at the price of $47.91 with 0.78% change on the day. The Fort Worth Texas 76155 based company is currently trading 93.86% above its 52 week low of $24.85 and -5.39% below its 52 week high of $50.64. Both the RSI indicator and target price of 52.97 and $53.73 respectively, lead us to believe that it should be put on hold over the coming weeks.

American Airlines Group Inc., through its subsidiaries, operates in the airline industry. As of December 31, 2015, the company operated a mainline fleet of 946 aircraft. It serves 350 destinations in approximately 50 countries. The company was formerly known as AMR Corporation and changed its name to American Airlines Group Inc. in December 2013. American Airlines Group Inc. was founded in 1934 and is headquartered in Fort Worth, Texas.

Mylan N.V. (MYL) traded within a range of $35.98 to $36.64 after opening the day at $36. The company has seen its stock decrease in value by -4.38% so far this year. The stock was up close to 1.87% on light volume in last trading session and closed at $36.48 per share. After the recent gain, the stock is currently holding -32.73% below its 52 week high of $53.92 and 8.57% above its 12-month low of $33.6. The shares are down by over -2.88% in the last three months, and the RSI indicator value of 43.51 is neither bullish nor bearish, tempting investors to stay on the sidelines.

Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals worldwide. The company provides generic or branded generic pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, cream, or ointment forms, as well as active pharmaceutical ingredients (APIs). It is also involved in the development of APIs with non-infringing processes for internal use and to partner with manufacturers; and manufacture and sale of injectable products in antineoplastics, anti-infectives, anesthesia/pain management, and cardiovascular therapeutic areas. In addition, the company produces finished dosage form and oral solid dose products; and offers antiretroviral therapies to third parties. Further, it manufactures and sells branded specialty injectable and nebulized products comprising EpiPen Auto-Injector to treat severe allergic reactions; Perforomist Inhalation Solution, a formoterol fumarate inhalation solution for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder patients; and ULTIVA, an analgesic agent used during the induction and maintenance of general anesthesia for inpatient and outpatient procedures. It sells generic pharmaceutical products to proprietary and ethical pharmaceutical wholesalers and distributors, group purchasing organizations, drug store chains, independent pharmacies, drug manufacturers, institutions, and public and governmental agencies; and specialty pharmaceuticals to pharmaceutical wholesalers and distributors, pharmacies, and healthcare institutions. Mylan N.V. has a collaboration agreement with Momenta Pharmaceuticals, Inc. to develop, manufacture, and commercialize Momenta Pharmaceuticals, Inc.’s biosimilar candidates. The company was formerly known as New Moon B.V. Mylan N.V. was founded in 1961 and is based in Hertfordshire, the United Kingdom.

 

3 Trending Stocks: Mylan N.V. (MYL), Brocade Communications Systems, Inc. (BRCD), Cabot Oil & Gas Corporation (COG)

Mylan N.V. (MYL) continued its downward trend with the stock declining -0.61% or $-0.22 to close the day at $35.81 on light trading volume of 5.07M shares, compared to its three month average trading volume of 5.79M. The Hatfield Hertfordshire EN6 1AG based company has been underperforming the drugs – generic group over the past 52 weeks, with the stock losing -31.95%, compared to the industry which has dropped -19.9% over the same period. With RSI of 37.38, the stock should still continue to rise and get closer to its one year target estimate of $49.84, making it a hold for now.

Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals worldwide. The company provides generic or branded generic pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, cream, or ointment forms, as well as active pharmaceutical ingredients (APIs). It is also involved in the development of APIs with non-infringing processes for internal use and to partner with manufacturers; and manufacture and sale of injectable products in antineoplastics, anti-infectives, anesthesia/pain management, and cardiovascular therapeutic areas. In addition, the company produces finished dosage form and oral solid dose products; and offers antiretroviral therapies to third parties. Further, it manufactures and sells branded specialty injectable and nebulized products comprising EpiPen Auto-Injector to treat severe allergic reactions; Perforomist Inhalation Solution, a formoterol fumarate inhalation solution for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder patients; and ULTIVA, an analgesic agent used during the induction and maintenance of general anesthesia for inpatient and outpatient procedures. It sells generic pharmaceutical products to proprietary and ethical pharmaceutical wholesalers and distributors, group purchasing organizations, drug store chains, independent pharmacies, drug manufacturers, institutions, and public and governmental agencies; and specialty pharmaceuticals to pharmaceutical wholesalers and distributors, pharmacies, and healthcare institutions. Mylan N.V. has a collaboration agreement with Momenta Pharmaceuticals, Inc. to develop, manufacture, and commercialize Momenta Pharmaceuticals, Inc.’s biosimilar candidates. The company was formerly known as New Moon B.V. Mylan N.V. was founded in 1961 and is based in Hertfordshire, the United Kingdom.

Brocade Communications Systems, Inc. (BRCD) climbed 0.08% during last trading as the stock added $0.01 to finish the day at $12.47 with about 5.07M shares changing hands, compared to its three month average trading volume of 9.05M. The $5.06B market cap company, which fluctuated between $12.45 and $12.5 during the day, currently situated 68.01% above its 52 week low of $7.58 and -0.56% away from its one year high of $12.54. The RSI of 52.69 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

Brocade Communications Systems, Inc. provides storage area networking (SAN) and Internet protocol (IP) networking solutions for businesses and organizations worldwide. It operates through three segments: SAN Products, IP Networking Products, and Global Services. The SAN Products segment offers infrastructure products and solutions, such as fiber channel SAN backbones, directors, and fabric/embedded switches that assist customers in the development and deployment of storage and server consolidation, disaster recovery, and data security, as well as to meet compliance requirements regarding data management; and FC fabric extension, analytics, switching, and routing solutions. The IP Networking Products segment provides Layer 2 and Layer 3 Ethernet switches and routers to connect users over private and public networks, including local area, metro, and within and across data centers. This segment also provides converged network products; a portfolio of related software and hardware-based data networking offerings; Layer 4-7 products that are designed for application traffic management and server load balancing; and a range of wireless products for the network edge. The Global Services segment offers break/fix maintenance, installation, consulting, network management and software maintenance, and customer support services. The company serves various enterprises and service providers, such as telecommunication firms, cable operators, and mobile carriers. The company markets and sells its products and services to end-user customers directly, as well as through various distribution partners, including original equipment manufacturers, distributors, systems integrators, and value-added resellers. Brocade Communications Systems, Inc. was founded in 1995 and is headquartered in San Jose, California.

Cabot Oil & Gas Corporation (COG) saw its value increase by 3.56% as the stock gained $0.79 to finish the day at a closing price of $22.97. The stock was lighter in trading and has fluctuated between $18.48-$26.74 per share for the past year. The shares, which traded within a range of $22.35 to $23.09 during the day, are up by 7.59% in the past three months and down by -2.37% over the past six months. It is currently trading 2.5% above its 20 day moving average and 1.9% above its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $28.01 a share over the next twelve months. The current relative strength index (RSI) reading is 55.96. The technical indicator lead us to believe there will be no major movement any time soon, hold.

Cabot Oil & Gas Corporation, an independent oil and gas company, develops, exploits, explores for, produces, and markets natural gas, oil, and natural gas liquids in the United States. The company primarily focuses on the Marcellus Shale in northeast Pennsylvania with approximately 200,000 net acres in the dry gas window of the play; and the Eagle Ford Shale in south Texas with approximately 85,500 net acres in the oil window of the play. It also transports, stores, gathers, and purchases natural gas for resale. The company sells its natural gas to industrial customers, local distribution companies, and gas marketers through gathering systems and pipelines, as well as to intrastate pipelines, natural gas processors, and marketing companies. As of December 31, 2015, it had proved reserves of approximately 8,190 billion cubic feet of natural gas equivalent. The company was founded in 1989 and is headquartered in Houston, Texas.